Li Q et al[23] showed that nuclear PKM2 can promote gefitinib resistance in colorectal cancer by up-regulating STAT3 activation, but whether it has the same effect in HCC remains to be further studied. This evidence concerns the gene PKM and hepatocellular carcinoma.